Form 4: ProMIS CEO Warma Acquires Shares, Warrants

ProMIS Neurosciences Inc. CEO Neil K Warma acquired 6,183 common shares and an equal number of warrants in a transaction dated February 3, 2026.

Summary

• Neil K Warma, Chief Executive Officer and Director of ProMIS Neurosciences Inc. (PMN), acquired 6,183 common shares and 6,183 common share purchase warrants.
• The acquisition was made on February 3, 2026, pursuant to a Securities Purchase Agreement between the company and selected investors.
• The purchase price for each common share and common share warrant was $12.13.
• The common share warrants have an exercise price of $14.40 per share.
• The warrants will expire on February 3, 2031, or earlier, within 60 days of the public announcement of topline data from cohorts treated with single ascending doses of PMN310.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to the CEO's personal investment, which signals confidence. The warrant structure also suggests a belief in future stock appreciation.

Positives

• The Chief Executive Officer and Director, Neil K Warma, increased his direct beneficial ownership in the company, signaling confidence in its future prospects.
• The acquisition was part of a broader Securities Purchase Agreement, indicating the company successfully raised capital from investors.

Negatives

• The warrant exercise price of $14.40 is higher than the purchase price of $12.13, meaning the stock price needs to appreciate for the warrants to be in-the-money.

Risks

• The expiration of the common share warrants is tied to the public announcement of topline data from PMN310 cohorts, introducing clinical trial risk.
• The value of the warrants is contingent on the future performance of PMN310 and the company's stock price exceeding the exercise price.

Future Outlook

The future outlook for the warrants is directly linked to the progress and public announcement of topline data from the PMN310 clinical trial, which could trigger an earlier expiration of the warrants.

Management Comments

• Neil K Warma, as CEO, demonstrated personal investment in the company's future by acquiring additional shares and warrants.

Industry Context

StockSavvy.ai notes that insider buying, especially by a CEO, is often interpreted by the market as a strong signal of management's confidence in the company's valuation and future prospects, potentially indicating an undervaluation or anticipated positive developments.

Related Party Transactions

• Neil K Warma, the Chief Executive Officer and a Director, acquired securities directly from ProMIS Neurosciences Inc. as part of a Securities Purchase Agreement.

Stakeholder Impact

• Shareholders may view the CEO's increased stake as a positive indicator of management's belief in the company's future, potentially boosting investor confidence.
• The capital raise through the Securities Purchase Agreement provides additional funding for the company's operations and strategic initiatives.

Next Steps

• Monitoring the progress and eventual public announcement of topline data from the PMN310 cohorts, which will impact the warrant expiration.

Key Dates

Recommendation

A seasoned investor would view the CEO's personal acquisition of shares and warrants as a strong vote of confidence in ProMIS Neurosciences Inc.'s future. Insider buying, particularly by top executives, often precedes positive company developments or indicates a belief that the stock is undervalued. This action suggests management sees significant upside potential, making it a compelling signal for a 'buy' recommendation.

Keywords

ProMIS Neurosciences, PMN, Insider Buying, Form 4, CEO Stock Purchase, Warrants, Securities Purchase Agreement, PMN310, Biotechnology, Neuroscience